TY - JOUR
T1 - How common is breast implant-associated anaplastic large cell lymphoma? First four cases in Israel
AU - Naftali, Yeela Ben
AU - Barnea, Yoav
AU - Clemens, Mark W.
AU - Bar-Meir, Eran
N1 - Publisher Copyright:
© 2019 Israel Medical Association. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Breast implant-associated anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin's lymphoma that is found around breast implants. ALCL was discovered only two decades ago. In Israel we have had four diagnosed cases (as of 2018). Until recently, the estimated incidence was 1:300,000 women with breast implants, while recent reports range from 1:3817 to 1:30,000. Objectives: To determine the occurrence of breast implant-ALCL in Israel. Methods: We conducted a retrospective analysis of the four patients diagnosed with ALCL in Israel. Cytology was confirmed and the clinical data was collected. Based on the estimated number of women with breast implants in Israel, a calculation of the true incidence was completed. Results: The incidence in Israel is significantly higher than the older incidence reports indicate. We estimated that the lifetime prevalence of the disease is 4:60,000 women with a textured breast implant, or 1:15,000 women with a textured breast implant in Israel. Conclusions: ALCL is not common. We support the claim that the prevalence is significantly higher than what was initially described. This finding has clinical and medicolegal implications that should be addressed accordingly.
AB - Background: Breast implant-associated anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin's lymphoma that is found around breast implants. ALCL was discovered only two decades ago. In Israel we have had four diagnosed cases (as of 2018). Until recently, the estimated incidence was 1:300,000 women with breast implants, while recent reports range from 1:3817 to 1:30,000. Objectives: To determine the occurrence of breast implant-ALCL in Israel. Methods: We conducted a retrospective analysis of the four patients diagnosed with ALCL in Israel. Cytology was confirmed and the clinical data was collected. Based on the estimated number of women with breast implants in Israel, a calculation of the true incidence was completed. Results: The incidence in Israel is significantly higher than the older incidence reports indicate. We estimated that the lifetime prevalence of the disease is 4:60,000 women with a textured breast implant, or 1:15,000 women with a textured breast implant in Israel. Conclusions: ALCL is not common. We support the claim that the prevalence is significantly higher than what was initially described. This finding has clinical and medicolegal implications that should be addressed accordingly.
KW - Anaplastic large cell lymphoma (ALCL)
KW - Breast cancer
KW - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
KW - Non-Hodgkin's lymphoma
UR - https://www.scopus.com/pages/publications/85071739593
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31474008
AN - SCOPUS:85071739593
SN - 1565-1088
VL - 21
SP - 512
EP - 515
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 8
ER -